Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Bethany Veo"'
Autor:
Li Lu, Anantha Marisetty, Bin Liu, Mohamed Mostafa Kamal, Joy Gumin, Bethany Veo, YouQing Cai, Dina Hamada Kassem, Connie Weng, Mark E. Maynard, Kimberly N. Hood, Gregory N. Fuller, Zhizhong Z. Pan, Matthew D. Cykowski, Pramod K. Dash, Sadhan Majumder
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/df9490dd876447009a34d32ef21ffdea
Autor:
Swapna Asuthkar, Sujatha Venkataraman, Janardhan Avilala, Katherine Shishido, Rajeev Vibhakar, Bethany Veo, Ian J. Purvis, Maheedhara R. Guda, Kiran K. Velpula
Publikováno v:
Cancers; Volume 14; Issue 7; Pages: 1673
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Maximum safe resection, postoperative craniospinal irradiation, and chemotherapy are the standard of care for MB patients. MB is classified into four subgroups: Shh, Wnt, Group
Publikováno v:
Neuro-Oncology. 24:i122-i123
Medulloblastoma (MB) is the most prevalent malignant brain tumor in children and demonstrates a high level of heterogeneity. Treatment for MB includes chemotherapy and radiation often resulting in long-term morbidity. MYC-driven MB, are high-risk tum
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy
Autor:
Susan Fosmire, Sujatha Venkataraman, Irina Alimova, Nicholas K. Foreman, Bethany Veo, Dong Wang, Angela Pierce, Kelly D. Sullivan, Andrew M. Donson, Rajeev Vibhakar, Mark Erlander, Krishna Madhavan, Maya Ridinger, Molishree Joshi, Ilango Balakrishnan
Publikováno v:
Neuro Oncol
Background Group 3 medulloblastoma (MB) is often accompanied by MYC amplification. PLK1 is an oncogenic kinase that controls cell cycle and proliferation and has been preclinically validated as a cancer therapeutic target. Onvansertib (PCM-075) is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ad64285b0702b156a7caef68993eaf
https://europepmc.org/articles/PMC8917408/
https://europepmc.org/articles/PMC8917408/
Autor:
Andrew Morin, Darya Wodetzki, Bethany Veo, Angela Pierce, Shadi Zahedi, Michele Crespo, Sujatha Venkataraman, Rajeev Vibhakar, Jean Mulcahy-Levy
Publikováno v:
Neuro-Oncology. 24:i8-i8
Atypical teratoid/rhabdoid tumors (AT/RT) are CNS tumors with a 5-year survival of ~35%. AT/RT is characterized by loss-of-function mutations in the SMARCB1 component of the SWI/SNF (SWItch/Sucrose Non-Fermentable) complex. Based on preliminary CRISP
Publikováno v:
Neuro-Oncology. 24:i125-i125
Cyclin-dependent kinase 8 (CDK8) belongs to the transcription-related cyclin dependent protein kinase family. CDK8 and cyclin C associate with the mediator complex to regulate gene transcription. Although CDK8 has been shown to be implicated in the m
Publikováno v:
Neuro-Oncology. 24:i125-i125
We explored an shRNA library screen on 20 cyclin-dependent kinases to establish cyclin-dependent kinase 11 (CDK11) as a critical mediator in MYC-driven medulloblastoma. The effect and molecular mechanism of CDK11 in the proliferation and growth of me
Autor:
Kelly D. Sullivan, Bethany Veo, Sujatha Venkataraman, Sana D. Karam, Susan Fosmire, Molishree Joshi, Rajeev Vibhakar, Etienne Danis, Dong Wang, Natalie J. Serkova, Angela Pierce, Nathan Dahl, Santosh Khanal
Publikováno v:
Cell reports. 35(4)
MYC-driven medulloblastoma is a major therapeutic challenge due to frequent metastasis and a poor 5-year survival rate. MYC gene amplification results in transcriptional dysregulation, proliferation, and survival of malignant cells. To identify thera
Autor:
Natalie J. Serkova, Angela Pierce, Susan Fosmire, Kelly D. Sullivan, Etienne Danis, Santosh Khanal, Sana D. Karam, Dong Wang, Sujatha Venkataraman, Nathan Dahl, Bethany Veo, Rajeev Vibhakar, Molishree Joshi
Myc-driven Medulloblastoma remains a major therapeutic challenge due to frequent metastasis and a poor 5-year survival rate. Myc gene amplification results in transcriptional dysregulation, proliferation, and survival of malignant cells. To identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162d5587bb0f5c71a6ad88a6809831ea
Autor:
Bethany Veo, Andrew Morin, Jean M. Mulcahy Levy, Rajeev Vibhakar, Susan Fosmire, Shadi Zahedi, Michele Crespo
Publikováno v:
Neuro-Oncology
Atypical teratoid/rhabdoid tumors (AT/RT) are characterized by loss-of-function mutations in the SMARCB1 component (and less commonly SMARCA4) of the SWI/SNF chromatin-remodeling complex. AT/RT demonstrate an overall silent genomic landscape with epi